Vesicare
5 customer reviewsVesicare is a prescription medicine containing solifenacin succinate, an antimuscarinic used for overactive bladder. It is for adults with urgency, frequent urination, nocturia, or urge incontinence. It helps by relaxing the bladder muscle to reduce urgent signals and leakage.
What is it?
Vesicare, containing the active ingredient Solifenacin succinate, is a medication used to treat overactive bladder (OAB) symptoms like urinary urgency, frequency, and incontinence. It is used by adults whose bladder symptoms interfere with daily activities and sleep. It works by relaxing the bladder muscle so the bladder can hold more urine and send fewer “urgent” signals.
Composition
Vesicare contains the active substance solifenacin succinate, an antimuscarinic (anticholinergic) agent. Depending on the prescribed strength, each tablet provides solifenacin as solifenacin succinate in standard doses (commonly 5 mg or 10 mg solifenacin). Tablets also include inactive excipients that form the core and film coating to ensure stability, swallowing, and consistent release.
How to use?
Vesicare tablets are taken by mouth once daily, and Vesicare can be taken with or without food. Most prescribers start at a lower dose and adjust based on response and side effects. Dose selection matters in people who are sensitive to constipation, have glaucoma risks, or take interacting medicines.
Key administration points that make a real difference:
- Take it at a consistent time each day to keep symptoms steadier across day and night.
- Swallow tablets with water.
- If dry mouth is intense, taking Vesicare earlier in the day can feel easier for some patients, since nighttime dryness can disturb sleep.
Common patient mistakes with dosing
People often stop after a few days because they still feel urgency. Others increase the dose on their own when they have a bad day. Both patterns tend to backfire by either preventing benefit or raising side effects without a plan.
How does it work?
Vesicare contains Solifenacin succinate, an antimuscarinic medicine. In simple terms, it blocks muscarinic (M3) receptors that respond to the neurotransmitter acetylcholine in the bladder.
The detrusor muscle is the bladder’s “squeezer.” In OAB, it can contract at the wrong time. Solifenacin reduces these involuntary contractions, so the bladder:
- holds more urine before signaling urgency
- contracts less often without warning
- leaks less from sudden urges
A dry mouth can be a sign the medicine is “hitting” muscarinic receptors in salivary glands too. It’s common and manageable, but it also tells you why constipation and blurred vision can happen.
Indications
Vesicare is a prescription urinary tract medication used for overactive bladder (OAB). OAB is a symptom pattern, not an infection, and it usually includes a sudden strong urge to pass urine, going too often, waking at night to urinate, and leakage before you reach the toilet.
Vesicare is used to help with:
- Urgency: the “got to go now” feeling
- Frequency: needing to urinate more often than usual
- Urge incontinence: leakage linked to urgency
- Nocturia: waking from sleep to urinate
Comparison
If Vesicare is not a good fit due to side effects, interactions, or incomplete symptom control, clinicians often consider other pharmacologic options or a switch in drug class.
Common alternatives for OAB include:
- Tolterodine (antimuscarinic): similar goal, side effects often similar but individual tolerability differs.
- Oxybutynin (antimuscarinic): can be effective, yet dry mouth and cognitive side effects can be more limiting for some people.
- Mirabegron (beta-3 agonist): works through a different receptor pathway and may suit people who cannot tolerate antimuscarinics, though it can raise blood pressure in some patients.
Non-drug approaches are not “soft options.” Bladder training, pelvic floor physiotherapy, and fluid timing changes can materially reduce urgency and nocturia, and they combine well with medication.
| Option | How it works | Common drawbacks |
|---|---|---|
| Vesicare (solifenacin) | Antimuscarinic relaxes detrusor muscle | Dry mouth, constipation, blurred vision |
| Tolterodine | Antimuscarinic for bladder overactivity | Dry mouth, constipation, dizziness |
| Oxybutynin | Antimuscarinic; stronger systemic effects in some | Dry mouth, constipation, sedation/cognitive effects |
Contraindications
- Urinary retention or inability to empty the bladder
- Gastric retention (severe stomach emptying delay)
- Uncontrolled narrow-angle glaucoma
Not recommended for
Vesicare may not be suitable if you cannot empty your bladder properly, have severe constipation or gut “slowing,” or have certain types of glaucoma.
You also need extra medical supervision if you have an enlarged prostate or other blockage symptoms (weak stream or high residual urine), kidney or liver problems, or a history of heart-rhythm issues such as QT prolongation. If your bowels “stop,” bladder symptoms can worsen, so constipation management is important.
Side effects
Side effects come from antimuscarinic activity in organs outside the bladder. Most are dose-related, and many ease after the first weeks.
Common side effects reported with solifenacin include:
- Dry mouth
- Constipation
- Blurred vision (Solifenacin may cause blurred vision, so be careful with driving until you know your response)
- Drowsiness or dizziness in some people
- Indigestion or nausea
- Urinary retention (rare, but important)
Serious effects are uncommon, but they need prompt assessment:
- Inability to pass urine or painful bladder fullness (possible retention)
- Severe constipation with abdominal pain or vomiting
- Fast or irregular heartbeat, fainting, or severe dizziness
- Sudden eye pain with vision changes (a red-flag for narrow-angle glaucoma)
One practical nuance from pharmacy experience: antimuscarinics can quietly worsen constipation until it becomes a “day 10 problem.” People often notice bladder improvement first, then get hit by bowel symptoms.
Common mistakes
Small missteps can erase the benefit.
- Stopping too early: OAB symptoms often improve over weeks, not overnight.
- Doubling after a missed dose: This raises side effects without improving control.
- Ignoring constipation: Constipation can worsen urgency and frequency.
- Taking multiple “drying” medicines together: Cold/flu antihistamines and some sleep aids add anticholinergic load and can intensify dry mouth, blurred vision, and retention.
- Assuming urgency equals infection: Treating with leftover antibiotics delays correct OAB management and misses other diagnoses.
Doctor opinions
In clinical practice, urologists and primary care clinicians often treat OAB as a long game: the goal is fewer urgency episodes, fewer bathroom “mapping” behaviours, and better sleep. Doctors also watch for the trade-off—Vesicare can improve urgency and leakage, yet dry mouth and constipation can limit how far you can push the dose.
One pattern clinicians mention is “symptom overlap.” OAB can coexist with prostate enlargement, pelvic organ prolapse, diabetes, or diuretic use, so prescribers may adjust the plan rather than simply escalating Vesicare. Guidance frameworks aligned with WHO health priorities in healthy ageing place strong emphasis on falls prevention; blurred vision or dizziness from anticholinergic burden becomes relevant in older adults who already feel unsteady at night [2].
Another real-world point: a patient may report “it didn’t work,” but their voiding diary shows fewer leak episodes and fewer urgent runs to the bathroom. Doctors often use diaries because the benefit can be gradual and easy to miss day-to-day.
Frequently asked questions
Take the next dose at your usual time the following day. Avoid taking two doses on the same day, since that raises the chance of dry mouth, constipation, and blurred vision without giving extra symptom control. If missed doses happen often, linking the tablet to a daily habit (breakfast or brushing teeth) tends to improve consistency. Medication adherence recommendations used in MOHAP patient-safety frameworks in 2026 support simplifying routines to reduce dosing errors .
Long-term use is common in OAB when symptoms return after stopping. The key long-term issue is “anticholinergic burden,” which means the combined effect of all medicines with antimuscarinic properties, especially in older adults. Your clinician may review your full medicine list and aim for the lowest dose that still controls urgency and leakage. WHO healthy ageing and medication safety priorities used in 2026 place special focus on reducing medicines that increase falls risk and confusion in susceptible patients .
Weight gain is not a classic effect of solifenacin, and most people do not see a clear change directly from Vesicare. Some people feel abdominal bloating from constipation, which can look like weight gain on the scale for a few days. If you notice swelling of legs, sudden weight changes, or shortness of breath, those symptoms are not typical OAB medication effects and need medical assessment. Clinical counselling resources used by major health systems in 2026 still list dry mouth and constipation as the expected pattern rather than metabolic changes [4].
Alcohol does not have a direct chemical incompatibility with solifenacin, but the combination can amplify dizziness, sleep disruption, and the risk of falls when you wake at night to urinate. Alcohol can also irritate the bladder and worsen urgency in some people, masking how well Vesicare is working. If nocturia is your main issue, reducing evening alcohol is one of the fastest non-drug wins. This advice is consistent with patient guidance used in large clinical education centres in 2026 [5].
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Vesicare — Comparison with alternatives
Vesicare Current Best rated
Travatan Best price
Tecfidera
Combigan
CellCept
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2026). Solifenacin: European public assessment and product information summary for overactive bladder therapy. ↑
- World Health Organization (WHO) (2026). Medication safety in older adults: anticholinergic burden, falls risk, and practical risk-reduction. ↑
- MOHAP (Ministry of Health and Prevention) (2026). Patient Medication Safety Guidance: maintaining medication lists and preventing clinically relevant interactions. ↑
- Cleveland Clinic (2026). Solifenacin Tablets: uses, side effects, and patient guidance for overactive bladder. ↑
- NICE (UK National Institute for Health and Care Excellence) (2025). Urinary incontinence and pelvic organ prolapse in women: management and overactive bladder medicines. ↑